

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project (RPP) decision paper

Review of TA292; Aripiprazole for the treatment of acute manic and mixed episodes in children with bipolar disorder

Final recommendation post consultation
TA292 should be transferred to the static guidance list.

1. Background

This guidance was issued in July 2013

At the Guidance Executive meeting of 27 June 2017 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The guidance should be transferred to the 'static guidance list'. We should consult on this proposal.

3. Rationale for selecting this proposal

The new evidence identified from the literature searches and registered trials does not indicate that a review of the recommendations in technology appraisal 292 is needed. In addition, the marketing authorisation has not changed and the original prices for aripiprazole used in TA292 are broadly in line with current prices. It is therefore proposed that technology appraisal guidance 292 is transferred to the 'static guidance list'

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: Department of Health Response to proposal: No comment.</p>	<p>Comment from Technology Appraisals No comment.</p>
<p>Respondent: Otsuka Pharmaceutical Europe Ltd. Response to proposal: Agree Otsuka agree that in the absence of new data, it is appropriate to move the guidance to the static list.</p>	<p>Comment from Technology Appraisals Commented noted. The guidance will be moved to the static list.</p>
<p>Respondent: Wockhardt UK Ltd Response to proposal: No comment.</p>	<p>Comment from Technology Appraisals No comment.</p>
<p>Respondent: Teva UK Limited Response to proposal: No comment We had no further comments and we are happy with the move to the static list.</p>	<p>Comment from Technology Appraisals Comment noted. The guidance will be moved to the static list.</p>

Paper signed off by: Jenniffer Prescott, 10 August 2017

Contributors to this paper:

Technical Lead: Stuart Wood

Technical Adviser: Eleanor Donegan

Project Manager: Samantha Shannon